The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Alibaba Group ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Analysts from Cantor Fitzgerald downgraded Merck’s FY2025 EPS forecast from $8.88 to $8.66 while maintaining a cautious ...

Merck's animal health division received Food and Drug Administration approval for its once-yearly injectable flea-and-tick treatment for dogs. Merck Animal Health said Thursday it expects its Bravecto ...

VFLO applies a free cash flow strategy with a sector tilt toward energy and healthcare, offering value at a discount. Find ...

Detailed price information for Verona Pharma Plc ADR (VRNA-Q) from The Globe and Mail including charting and trades.

Merck acquired Verona Pharma for $10 billion, focusing on Verona’s first-in-class COPD drug, Ohtuvayre. Ohtuvayre’s rapid ...

Real-time index price for TSX American Preferred Stock Index (STNC), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

The Dow Jones Industrial Average is climbing Wednesday afternoon with shares of Boeing and Merck seeing positive momentum for the price-weighted average.

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.